(Q38116065)

29 August 2017

title

Monoclonal antibody treatments for rheumatoid arthritis (English)

1 reference

29 August 2017

0 references

1 reference

Lukas Bossaller

1

1 reference

29 August 2017

Achim Rothe

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

21 June 2013

1 reference

Expert Opinion on Biological Therapy

29 August 2017

published in

1 reference

29 August 2017

volume

13

1 reference

29 August 2017

issue

9

1 reference

29 August 2017

page(s)

1257-1272

1 reference

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

FcRn: the neonatal Fc receptor comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Post-translational modifications in the context of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Engineered antibody fragments and the rise of single domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

The impact of PEGylation on biological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

A new generation of protein display scaffolds for molecular recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Development trends for human monoclonal antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Human antibodies from transgenic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Selecting and screening recombinant antibody libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

In vitro display technologies reveal novel biopharmaceutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

In-vitro protein evolution by ribosome display and mRNA display

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Crystal structure of an in vitro affinity- and specificity-matured anti-testosterone Fab in complex with testosterone. Improved affinity results from small structural changes within the variable domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Belimumab--an anti-BLyS human monoclonal antibody for rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

High-throughput antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Pharmacokinetics of rituximab and its clinical use: thought for the best use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Lymph node IL-18 expression in adult-onset Still's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Regulation of the B cell receptor repertoire and self-reactivity by BAFF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

The clinical utility of inhibiting CD28-mediated costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Clinical targeting of the TNF and TNFR superfamilies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Biologic therapies in rheumatology: lessons learned, future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Blocking interleukin-1 in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Update on biologicals for treatment of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

The sterile inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Activation and regulation of the inflammasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Gout-associated uric acid crystals activate the NALP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Which are the antibodies to watch in 2013?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Response of Th17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Type 17 T helper cells-origins, features and possible roles in rheumatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Mechanisms of Disease: the link between RANKL and arthritic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Osteoporosis: now and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Emerging targets of biologic therapies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

DAMPs, PAMPs and alarmins: all we need to know about danger

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Beneficial suicide: why neutrophils die to make NETs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Neutrophil extracellular traps kill bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

The advent of biosimilar therapies in rheumatology—“O Brave New World”

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Abatacept Limits Breach of Self-Tolerance in a Murine Model of Arthritis via Effects on the Generation of T Follicular Helper Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.811230

10.1517/14712598.2013.811230

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference